CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | unsaturated fatty acid |
|
Accession: | CHEBI:27208
|
browse the term
|
Definition: | Any fatty acid containing at least one C=C or C#C bond. |
Synonyms: | related_synonym: | alkene acid; olefinic acid; unsaturated fatty acids |
| xref: | LIPID_MAPS_class:LMFA0103; PMID:5322381 |
| cyclic_relationship: | is_conjugate_acid_of CHEBI:2580 |
|
|
|
G |
Polb |
DNA polymerase beta |
multiple interactions |
EXP |
nervonic acid binds to and results in decreased activity of POLB protein; nervonic acid binds to and results in decreased activity of POLB protein mutant form |
CTD |
PMID:16996474 |
|
NCBI chr16:69,379,438...69,402,710
Ensembl chr16:69,379,400...69,404,812
|
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Sorbic Acid results in increased expression of FOSL1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
EXP |
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IFNG mRNA |
CTD |
PMID:32179172 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IL10 mRNA |
CTD |
PMID:32179172 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IL1B mRNA |
CTD |
PMID:32179172 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of IL6 mRNA |
CTD |
PMID:32179172 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Orm1 |
orosomucoid 1 |
increases expression |
ISO |
Sorbic Acid results in increased expression of ORM1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154
|
|
G |
Phex |
phosphate regulating endopeptidase X-linked |
increases expression |
ISO |
Sorbic Acid results in increased expression of PHEX protein |
CTD |
PMID:20025956 |
|
NCBI chr X:37,607,553...37,856,183
Ensembl chr X:37,610,760...37,854,469
|
|
G |
Rad51ap1 |
RAD51 associated protein 1 |
increases expression |
ISO |
Sorbic Acid results in increased expression of RAD51AP1 protein |
CTD |
PMID:20025956 |
|
NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
[Food Preservatives results in increased abundance of Sorbic Acid] which results in increased expression of TNF mRNA |
CTD |
PMID:32179172 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression |
ISO |
Sorbic Acid results in increased expression of VEGFA protein |
CTD |
PMID:20025956 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in decreased expression of ALOX15 mRNA]] |
CTD |
PMID:34601004 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased expression of ALOX5 protein 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[[Dietary Fats co-treated with Cholesterol, Dietary] results in increased susceptibility to Silver Compounds] which results in decreased expression of ALOX5 mRNA] |
CTD |
PMID:17056761 PMID:34601004 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CCL2 protein] |
CTD |
PMID:21724996 PMID:34601004 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of CXCL2 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL2 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of CXCL2 protein]; [Silver Compounds results in increased susceptibility to 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid] which results in increased expression of CXCL2 mRNA |
CTD |
PMID:21724996 PMID:34601004 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of CXCL1 protein] |
CTD |
PMID:21724996 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ICAM1 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IFNG protein] |
CTD |
PMID:21724996 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of IL1B protein] |
CTD |
PMID:21724996 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 mRNA]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Dietary Fats co-treated with Cholesterol, Dietary] promotes the reaction [Silver Compounds results in increased expression of IL6 protein]]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [[Silver Compounds results in increased susceptibility to [Dietary Fats co-treated with Cholesterol, Dietary]] which results in increased expression of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 mRNA]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Silver Compounds results in increased expression of IL6 protein] |
CTD |
PMID:21724996 PMID:34601004 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgal |
integrin subunit alpha L |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of ITGAL mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein] |
CTD |
PMID:21724996 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of NFKBIA mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid binds to and affects the activity of PPARG protein |
CTD |
PMID:17056761 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased activity of RELA protein] |
CTD |
PMID:21724996 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases secretion |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid results in decreased secretion of TNF protein |
CTD |
PMID:17056761 PMID:21724996 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid inhibits the reaction [Dextran Sulfate results in increased expression of VCAM1 mRNA] |
CTD |
PMID:21724996 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
|
G |
Crp |
C-reactive protein |
affects expression |
ISO |
docosapentaenoic acid affects the expression of CRP protein |
CTD |
PMID:22113248 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
EXP |
docosapentaenoic acid inhibits the reaction [Ethanol results in decreased expression of PLA2G6 protein] |
CTD |
PMID:25029343 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
EXP |
docosapentaenoic acid results in decreased expression of PTGS2 protein docosapentaenoic acid inhibits the reaction [Dimethoate results in increased expression of PTGS2 protein] |
CTD |
PMID:22476691 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
docosapentaenoic acid binds to RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions increases abundance increases chemical synthesis |
EXP ISO |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:18984061 PMID:21193584 PMID:23872364 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:2849922 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
App |
amyloid beta precursor protein |
increases secretion multiple interactions |
ISO |
APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases chemical synthesis |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15613483 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases activity |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of EPHX2 protein |
CTD |
PMID:25600587 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] |
CTD |
PMID:15613483 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions affects activity |
EXP |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein |
CTD |
PMID:18984061 |
|
NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNB1 protein |
CTD |
PMID:18984061 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNC4 protein |
CTD |
PMID:18984061 |
|
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Krt1 |
keratin 1 |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] |
CTD |
PMID:12069687 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinin co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:25600587 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:25600587 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity affects localization multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:15451026 PMID:23355332 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPA mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPB mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid binds to and results in increased activity of PPARD protein |
CTD |
PMID:12069687 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases activity affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein |
CTD |
PMID:15451026 PMID:15613483 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity multiple interactions affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein |
CTD |
PMID:23355332 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
9,11-linoleic acid results in increased expression of CD36 mRNA |
CTD |
PMID:18155510 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Foxo1 |
forkhead box O1 |
affects localization |
ISO |
9,11-linoleic acid affects the localization of FOXO1 protein |
CTD |
PMID:15992797 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects binding |
ISO |
9,11-linoleic acid binds to PPARA protein |
CTD |
PMID:23843199 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
affects binding |
ISO |
9,11-linoleic acid binds to PPARB protein |
CTD |
PMID:23843199 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding increases activity |
ISO |
9,11-linoleic acid binds to PPARG protein 9,11-linoleic acid results in increased activity of PPARG protein |
CTD |
PMID:18155510 PMID:23843199 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
9,11-linoleic acid results in increased phosphorylation of and affects the localization of TP53 protein |
CTD |
PMID:15992797 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
affects binding |
EXP |
(E)-4-hydroxynon-2-enal binds to Gsta4 protein |
RGD |
PMID:11018474 |
RGD:1641942 |
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
affects binding |
EXP |
(E)-4-hydroxynon-2-enal binds to Gstp1 protein |
RGD |
PMID:11018474 |
RGD:1641942 |
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction |
ISO |
AKR1B1 protein results in increased reduction of 2,4-hexadienal; AKR1B1 protein results in increased reduction of 2,4-hexadienal metabolite |
CTD |
PMID:9890881 PMID:21329684 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases reduction |
ISO |
AKR1B10 protein results in increased reduction of 2,4-hexadienal; AKR1B10 protein results in increased reduction of 2,4-hexadienal metabolite |
CTD |
PMID:21329684 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Nxn |
nucleoredoxin |
affects response to substance |
ISO |
NXN gene SNP affects the susceptibility to 2,4-hexadienal |
CTD |
PMID:25622337 |
|
NCBI chr10:61,109,322...61,247,578
Ensembl chr10:61,110,020...61,248,251
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolenin results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolenin results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolenin results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolenin results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
ISO |
trilinolenin results in decreased expression of SCD1 mRNA |
CTD |
PMID:8729090 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCA1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG5 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
decreases expression |
ISO |
trilinolein results in decreased expression of ABCG8 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of CYP27A1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
increases expression |
ISO |
trilinolein results in increased expression of HMGCR mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
trilinolein results in increased expression of MTTP mRNA |
CTD |
PMID:18356535 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Npc1l1 |
NPC1 like intracellular cholesterol transporter 1 |
decreases expression |
ISO |
trilinolein results in decreased expression of NPC1L1 mRNA |
CTD |
PMID:18356535 |
|
NCBI chr14:81,071,448...81,091,113
Ensembl chr14:81,071,451...81,091,113
|
|
G |
Scd |
stearoyl-CoA desaturase |
multiple interactions decreases expression |
ISO |
Clofibrate inhibits the reaction [trilinolein results in decreased expression of SCD1 mRNA] |
CTD |
PMID:8790349 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-docosahexaenoyl-sn-glycero-3-phosphocholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Fech |
ferrochelatase |
affects abundance |
ISO |
FECH protein affects the abundance of 1-palmitoyl-2-linoleoylphosphatidylcholine |
CTD |
PMID:29906468 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of ACTA2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of ACTA2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; Resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:14769825 PMID:17550345 PMID:20103642 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]; Masoprocol inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lysophosphatidic acid results in increased abundance of Hydrogen Peroxide]] |
CTD |
PMID:10698703 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
[Lithocholic Acid co-treated with lysophosphatidic acid] results in increased activity of ALPL protein |
CTD |
PMID:19646460 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bcar1 |
BCAR1 scaffold protein, Cas family member |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of BCAR1 protein |
CTD |
PMID:11792571 |
|
NCBI chr19:39,679,215...39,713,907
Ensembl chr19:39,679,204...39,713,907
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
ISO |
lysophosphatidic acid analog results in increased expression of BCL2 protein; lysophosphatidic acid results in increased expression of BCL2 protein |
CTD |
PMID:23251428 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
C5 |
complement C5 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of HC protein |
CTD |
PMID:25822713 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
lysophosphatidic acid analog inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; lysophosphatidic acid inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein] |
CTD |
PMID:23251428 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl28 |
C-C motif chemokine ligand 28 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCL28 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:51,601,354...51,625,999
Ensembl chr 2:51,601,331...51,625,997
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CCN1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased expression of CCN2 protein N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 mRNA] Simvastatin inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of CCN2 protein] |
CTD |
PMID:15200425 PMID:24706986 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of COL1A2 mRNA N-(4-chlorophenyl)-1-((3-(furan-2-yl)phenyl)carbonyl)piperidine-3-carboxamide inhibits the reaction [lysophosphatidic acid results in increased expression of COL1A2 mRNA] |
CTD |
PMID:24706986 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Csf1 |
colony stimulating factor 1 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of CSF1 protein |
CTD |
PMID:25822713 |
|
NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL12 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL12 protein] |
CTD |
PMID:25822713 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl16 |
C-X-C motif chemokine ligand 16 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of CXCL16 protein 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of CXCL16 protein] |
CTD |
PMID:25822713 |
|
NCBI chr10:55,166,721...55,171,316
Ensembl chr10:55,166,723...55,171,592
|
|
G |
Cxcr1 |
C-X-C motif chemokine receptor 1 |
multiple interactions decreases expression |
ISO |
lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] lysophosphatidic acid results in decreased expression of CXCR1 mRNA |
CTD |
PMID:16224106 |
|
NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084
|
|
G |
Dgka |
diacylglycerol kinase, alpha |
multiple interactions |
ISO |
DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 7:1,148,734...1,175,324
Ensembl chr 7:1,148,735...1,175,110
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions increases phosphorylation |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions increases phosphorylation |
EXP |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; 2-butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:14769825 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions decreases expression |
ISO EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; 3-(2-methoxybenzylamino)-2-phenylpiperidine inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; [[Capsaicin results in increased chemical synthesis of Lysophosphatidylcholines] which results in increased secretion of Lysophosphatidylcholines] promotes the reaction [ENPP2 results in increased chemical synthesis of lysophosphatidic acid]; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2; [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid] which results in increased expression of ENPP2 mRNA; [ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid; [ENPP2 protein co-treated with Lysophosphatidylcholines] results in increased chemical synthesis of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid; [ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased chemical synthesis of and results in decreased abundance of lysophosphatidic acid; arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; bisindolylmaleimide I inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; Dizocilpine Maleate inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein]; U 0126 inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid]; xestospongin C inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 PMID:19014389 PMID:24599971 PMID:24747415 PMID:25398768 PMID:25896349 More...
|
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Epo |
erythropoietin |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
multiple interactions |
ISO |
FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] |
CTD |
PMID:18642114 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Gata1 |
GATA binding protein 1 |
multiple interactions |
ISO |
[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr X:14,529,706...14,537,530
Ensembl chr X:14,529,702...14,537,530
|
|
G |
Gna13 |
G protein subunit alpha 13 |
multiple interactions |
ISO |
GNA13 mutant form inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of EGFR protein] |
CTD |
PMID:23127547 |
|
NCBI chr10:94,337,939...94,370,774
Ensembl chr10:94,337,725...94,370,774
|
|
G |
Gypa |
glycophorin A |
multiple interactions |
ISO |
lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA] |
CTD |
PMID:21915944 |
|
NCBI chr19:27,450,304...27,465,940
Ensembl chr19:27,450,308...27,465,822
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
L-4F peptide inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of HIF1A protein] [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein; lysophosphatidic acid results in increased expression of HIF1A protein |
CTD |
PMID:17919812 PMID:22537771 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions increases phosphorylation |
EXP |
MK2i peptide inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein] |
CTD |
PMID:20864298 |
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
IL1B protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
lysophosphatidic acid results in increased secretion of IL6 protein |
CTD |
PMID:21821728 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Il6st |
interleukin 6 cytokine family signal transducer |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of IL6ST protein] |
CTD |
PMID:25822713 |
|
NCBI chr 2:44,065,979...44,106,255
Ensembl chr 2:44,066,130...44,109,936
|
|
G |
Kitlg |
KIT ligand |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of GYPA mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of GATA1 mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
EXP |
KNG1 protein inhibits the reaction [[Wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Lama3 |
laminin subunit alpha 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMA3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr18:3,523,168...3,751,722
Ensembl chr18:3,523,133...3,751,353
|
|
G |
Lamb3 |
laminin subunit beta 3 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMB3 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:104,833,810...104,875,405
Ensembl chr13:104,833,873...104,875,405
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
increases expression |
ISO |
lysophosphatidic acid results in increased expression of LAMC2 mRNA |
CTD |
PMID:15541073 |
|
NCBI chr13:65,284,664...65,344,164
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lpar1 |
lysophosphatidic acid receptor 1 |
increases response to substance multiple interactions |
ISO |
LPAR1 protein results in increased susceptibility to lysophosphatidic acid LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid inhibits the reaction [CXCR1 protein binds to LPAR1 protein]; lysophosphatidic acid results in decreased expression of [CXCR1 protein binds to LPAR1 protein] |
CTD |
PMID:16224106 PMID:16809448 PMID:25398768 |
|
NCBI chr 5:73,229,047...73,347,874
Ensembl chr 5:73,229,625...73,369,895
|
|
G |
Lpar3 |
lysophosphatidic acid receptor 3 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR3 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR3 protein |
CTD |
PMID:30102254 |
|
NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:235,149,065...235,193,357
|
|
G |
Lpar5 |
lysophosphatidic acid receptor 5 |
multiple interactions |
ISO |
Endocannabinoids inhibits the reaction [lysophosphatidic acid binds to and results in increased activity of LPAR5 protein]; lysophosphatidic acid binds to and results in increased activity of LPAR5 protein |
CTD |
PMID:30102254 |
|
NCBI chr 4:157,870,493...157,883,979
Ensembl chr 4:157,881,796...157,882,950
|
|
G |
Lpar6 |
lysophosphatidic acid receptor 6 |
multiple interactions |
ISO |
lysophosphatidic acid binds to and results in increased activity of LPAR6 protein |
CTD |
PMID:18297070 |
|
NCBI chr15:48,416,548...48,418,357
Ensembl chr15:48,416,544...48,422,331
|
|
G |
Lyve1 |
lymphatic vessel endothelial hyaluronan receptor 1 |
multiple interactions increases expression |
ISO |
3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of LYVE1 protein] lysophosphatidic acid results in increased expression of LYVE1 mRNA; lysophosphatidic acid results in increased expression of LYVE1 protein |
CTD |
PMID:18642114 |
|
NCBI chr 1:164,962,872...164,976,309
Ensembl chr 1:164,962,872...164,976,309
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
Hydrogen Peroxide promotes the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11243883 PMID:12657697 PMID:15081308 PMID:17919812 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mbp |
myelin basic protein |
multiple interactions |
EXP |
lysophosphatidic acid inhibits the reaction [ENPP2 mutant form results in decreased expression of MBP mRNA] |
CTD |
PMID:18594965 |
|
NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
increases phosphorylation |
EXP |
lysophosphatidic acid results in increased phosphorylation of MTOR protein |
CTD |
PMID:14769825 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myl9 |
myosin light chain 9 |
increases phosphorylation multiple interactions |
ISO |
lysophosphatidic acid results in increased phosphorylation of MYL9 protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of MYL9 protein] |
CTD |
PMID:24587105 |
|
NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333
|
|
G |
Mylk |
myosin light chain kinase |
affects response to substance |
ISO |
MYLK protein affects the susceptibility to lysophosphatidic acid |
CTD |
PMID:10640419 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO |
LPAR1 protein affects the reaction [lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein]; lysophosphatidic acid results in increased stability of and affects the localization of NFE2L2 protein [[ONO-8430506 results in decreased activity of ENPP2 protein] which results in decreased abundance of lysophosphatidic acid] which results in decreased expression of NFE2L2 |
CTD |
PMID:25398768 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions increases expression |
EXP |
Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein]; Y 27632 inhibits the reaction [lysophosphatidic acid results in increased expression of NPPA protein] |
CTD |
PMID:15081308 PMID:25449040 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Pak1 |
p21 (RAC1) activated kinase 1 |
increases activity multiple interactions |
EXP |
lysophosphatidic acid results in increased activity of PAK1 protein 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; diphenyleneiodonium inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Genistein inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PAK1 protein] |
CTD |
PMID:11855845 |
|
NCBI chr 1:152,111,172...152,226,390
Ensembl chr 1:152,111,188...152,226,383
|
|
G |
Pdpn |
podoplanin |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of PDPN mRNA; lysophosphatidic acid results in increased expression of PDPN protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PDPN protein] |
CTD |
PMID:18642114 |
|
NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of PECAM1 protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PECAM1 protein] |
CTD |
PMID:18642114 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Pip5k1a |
phosphatidylinositol-4-phosphate 5-kinase, type 1, alpha |
multiple interactions increases activity |
ISO |
1-Butanol inhibits the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein]; DGKA protein promotes the reaction [lysophosphatidic acid results in increased activity of PIP5K1A protein] |
CTD |
PMID:10913605 |
|
NCBI chr 2:182,628,299...182,671,584
Ensembl chr 2:182,628,300...182,671,598
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions increases expression |
ISO |
gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] |
CTD |
PMID:23127547 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions increases activity |
EXP |
1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]]; 1-Butanol inhibits the reaction [PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]]; bisindolylmaleimide I inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; Pertussis Toxin inhibits the reaction [lysophosphatidic acid results in increased activity of PLD1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK1 protein]; PLD1 protein affects the reaction [lysophosphatidic acid results in increased phosphorylation of MAPK3 protein]; toxB protein, Clostridium difficile inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PLD1 protein] |
CTD |
PMID:11243883 PMID:14769825 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Ppp1r12a |
protein phosphatase 1, regulatory subunit 12A |
increases phosphorylation multiple interactions |
EXP |
lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein Y 27632 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of PPP1R12A protein] |
CTD |
PMID:25449040 |
|
NCBI chr 7:43,482,808...43,593,689
Ensembl chr 7:43,482,803...43,593,425
|
|
G |
Prox1 |
prospero homeobox 1 |
increases expression multiple interactions |
ISO |
lysophosphatidic acid results in increased expression of PROX1 mRNA; lysophosphatidic acid results in increased expression of PROX1 protein 3-(4-dimethylamino-naphthalen-1-ylmethylene)-1,3-dihydro-indol-2-one inhibits the reaction [lysophosphatidic acid results in increased expression of PROX1 protein]; FLT4 protein affects the reaction [lysophosphatidic acid results in increased expression of PROX1 protein] |
CTD |
PMID:18642114 |
|
NCBI chr13:101,669,184...101,719,804
Ensembl chr13:101,669,184...101,711,183
|
|
G |
Ptk2 |
protein tyrosine kinase 2 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of PTK2 protein [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; KNG1 protein inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] [wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein; Atropine inhibits the reaction [oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein]]; oxotremorine M inhibits the reaction [[wortmannin co-treated with lysophosphatidic acid] results in increased phosphorylation of PTK2 protein] |
CTD |
PMID:10537051 PMID:11792571 |
|
NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
increases phosphorylation |
ISO |
lysophosphatidic acid results in increased phosphorylation of PTK2B protein |
CTD |
PMID:11792571 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Rhoa |
ras homolog family member A |
increases activity multiple interactions |
EXP ISO |
lysophosphatidic acid results in increased activity of RHOA protein Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOA protein] |
CTD |
PMID:15081308 PMID:24587105 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Rhoc |
ras homolog family member C |
multiple interactions increases activity |
ISO |
Farnesol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein]; geranylgeraniol analog inhibits the reaction [lysophosphatidic acid results in increased activity of RHOC protein] |
CTD |
PMID:24587105 |
|
NCBI chr 2:192,287,065...192,293,292
Ensembl chr 2:192,287,130...192,295,306
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation multiple interactions |
ISO EXP |
lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] 1-Butanol inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein]; exoenzyme C3, Clostridium botulinum inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:14769825 PMID:17919812 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA; [lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; lysophosphatidic acid promotes the reaction [[KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC mRNA]; Quercetin inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein]; WP1066 inhibits the reaction [[lysophosphatidic acid co-treated with KITLG protein co-treated with EPO protein] results in increased expression of TFRC protein] |
CTD |
PMID:21915944 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
ISO |
3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid inhibits the reaction [lysophosphatidic acid results in increased expression of TIMP1 protein] |
CTD |
PMID:25822713 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
TNF protein inhibits the reaction [lysophosphatidic acid results in decreased expression of ENPP2 protein] |
CTD |
PMID:25896349 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
increases expression multiple interactions |
ISO |
[lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA mRNA; [lysophosphatidic acid results in increased expression of HIF1A protein] which results in increased expression of VEGFA protein resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of VEGFA protein] |
CTD |
PMID:17919812 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
increases expression increases secretion |
ISO |
lysophosphatidic acid results in increased expression of VEGFC mRNA lysophosphatidic acid results in increased secretion of VEGFC protein |
CTD |
PMID:18642114 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance multiple interactions |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of 1-stearoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-palmitoyl-2-oleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases metabolic processing |
ISO |
DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases metabolic processing |
ISO |
DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases phosphorylation |
ISO |
DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:17455907 |
|
NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance |
ISO |
LIPC gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance |
ISO |
LIPG gene mutant form results in decreased abundance of 1-stearoyl-2-linoleoyl-sn-glycerol |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 protein results in increased susceptibility to 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases chemical synthesis |
ISO |
GPX4 protein results in increased chemical synthesis of 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] |
CTD |
PMID:12538810 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid] |
CTD |
PMID:20933508 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Tbxas1 |
thromboxane A synthase 1 |
multiple interactions |
ISO |
[Sulfasalazine results in decreased activity of TBXAS1 protein] which results in decreased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid |
CTD |
PMID:2572437 |
|
NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:67,665,007...67,837,096
|
|
|
G |
Cat |
catalase |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAT protein |
CTD |
PMID:10946007 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
increases expression |
ISO |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of CAV1 mRNA |
CTD |
PMID:27257344 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of CCL2 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of CCL2 protein |
CTD |
PMID:22135674 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
EXP |
[13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with 2-chloro-5-nitrobenzanilide] results in increased expression of EGR1 protein; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 mRNA; [13-hydroperoxy-9,11-octadecadienoic acid co-treated with MK-886] results in increased expression of EGR1 protein |
CTD |
PMID:22135674 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARA protein |
CTD |
PMID:22135674 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
EXP |
13-hydroperoxy-9,11-octadecadienoic acid results in increased expression of PPARG protein |
CTD |
PMID:22135674 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
affects metabolic processing |
ISO |
GSTA1 protein affects the metabolism of 13-oxo-9,11-octadecadienoic acid |
CTD |
PMID:12031293 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
affects metabolic processing |
ISO |
GSTA4 protein affects the metabolism of 13-oxo-9,11-octadecadienoic acid |
CTD |
PMID:12031293 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
EXP |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein |
CTD |
PMID:27428043 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein] |
CTD |
PMID:27428043 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions increases cleavage |
EXP ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7) 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form] |
CTD |
PMID:27428043 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein |
CTD |
PMID:16286479 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases chemical synthesis |
ISO |
CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:12675279 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions increases abundance |
ISO |
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:19896470 PMID:22680237 PMID:24472606 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein |
CTD |
PMID:16286479 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19464254 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19464254 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:16286479 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases secretion multiple interactions |
ISO |
TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:28694203 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of HMOX1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases activity |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of NQO1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction |
ISO |
AKR1B1 protein results in increased reduction of 2,4-nonadienal |
CTD |
PMID:9890881 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Gna15 |
G protein subunit alpha 15 |
multiple interactions increases response to substance |
ISO |
[GNA15 protein results in increased susceptibility to 2,4-nonadienal] which results in increased activity of OR1A1B protein |
CTD |
PMID:15598656 |
|
NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[PTGR1 protein co-treated with NADP] affects the reduction of 2,4-nonadienal |
CTD |
PMID:11524419 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Gna15 |
G protein subunit alpha 15 |
multiple interactions increases response to substance |
ISO |
[GNA15 protein results in increased susceptibility to 2,6-nonadienal] which results in increased activity of OR1A1B protein |
CTD |
PMID:15598656 |
|
NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,184,861...8,205,508
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of CASP3 mRNA |
CTD |
PMID:38462211 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 PMID:31024316 More...
|
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions |
ISO |
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egf |
epidermal growth factor |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of EGF mRNA; glyceryl 2-arachidonate affects the expression of EGF protein |
CTD |
PMID:38462211 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of FGF1 mRNA |
CTD |
PMID:38462211 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of GDNF mRNA; glyceryl 2-arachidonate affects the expression of GDNF protein |
CTD |
PMID:38462211 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases chemical synthesis multiple interactions |
ISO |
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:31408376 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate |
CTD |
PMID:27071101 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:26791602 PMID:30301768 More...
|
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
affects reduction increases reduction |
ISO |
AKR1B1 protein affects the reduction of 2-hexenal AKR1B1 protein results in increased reduction of 2-hexenal; AKR1B1 protein results in increased reduction of 2-hexenal metabolite |
CTD |
PMID:9890881 PMID:11306073 PMID:21329684 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases reduction |
ISO |
AKR1B10 protein results in increased reduction of 2-hexenal; AKR1B10 protein results in increased reduction of 2-hexenal metabolite |
CTD |
PMID:21329684 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c2 |
aldo-keto reductase family 1, member C2 |
increases expression |
ISO |
2-hexenal results in increased expression of AKR1C2 mRNA |
CTD |
PMID:20491607 |
|
NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases metabolic processing |
ISO |
ALDH1A1 protein results in increased metabolism of 2-hexenal |
CTD |
PMID:21256123 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases response to substance increases metabolic processing affects metabolic processing |
ISO |
ALDH3A1 protein results in decreased susceptibility to 2-hexenal ALDH3A1 protein results in increased metabolism of 2-hexenal ALDH3A1 protein affects the metabolism of 2-hexenal |
CTD |
PMID:11306050 PMID:21256123 |
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
2-hexenal results in increased expression of CYP1A1 mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Gsta1 |
glutathione S-transferase alpha 1 |
increases expression |
EXP |
2-hexenal results in increased expression of GSTA1 mRNA |
CTD |
PMID:9799558 |
|
NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
increases expression |
EXP |
2-hexenal results in increased expression of GSTA4 mRNA; 2-hexenal results in increased expression of GSTA4 protein |
CTD |
PMID:9799558 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
2-hexenal binds to and results in decreased activity of GSTP1 protein |
CTD |
PMID:9463521 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
2-hexenal results in increased expression of HMOX1 mRNA |
CTD |
PMID:20491607 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
2-hexenal results in increased expression of MAFF mRNA |
CTD |
PMID:20491607 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
[2,5-dihydro-2,4,5-trimethylthiazoline co-treated with 3-hexen-1-ol co-treated with 2-hexenal] results in decreased expression of POMC protein; [3-hexen-1-ol co-treated with 2-hexenal] inhibits the reaction [2,5-dihydro-2,4,5-trimethylthiazoline results in decreased expression of POMC protein]; [3-hexen-1-ol co-treated with 2-hexenal] results in decreased expression of POMC |
CTD |
PMID:19103229 PMID:21515296 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[PTGR1 protein co-treated with NADP] affects the reduction of 2-hexenal |
CTD |
PMID:11524419 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance |
ISO |
FABP1 protein affects the abundance of 2-oleoylglycerol |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Mgll |
monoglyceride lipase |
increases degradation multiple interactions |
EXP |
MGLL protein results in increased degradation of 2-oleoylglycerol Nitroglycerin promotes the reaction [MGLL protein results in increased degradation of 2-oleoylglycerol] |
CTD |
PMID:19515121 |
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction affects reduction |
ISO |
AKR1B1 protein results in increased reduction of 2-pentenal AKR1B1 protein affects the reduction of 2-pentenal |
CTD |
PMID:9890881 PMID:11306073 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[PTGR1 protein co-treated with NADP] affects the reduction of 2-pentenal |
CTD |
PMID:11524419 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein] |
CTD |
PMID:36368619 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Clock |
clock circadian regulator |
affects abundance |
ISO |
CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:22440902 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein |
CTD |
PMID:36368619 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:11124159 PMID:12388396 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
increases expression |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA |
CTD |
PMID:22442195 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
multiple interactions increases localization |
ISO EXP |
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein] |
CTD |
PMID:16055480 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP |
HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:18067589 PMID:19458537 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions increases phosphorylation |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:36368619 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein |
CTD |
PMID:36368619 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
4-hydroperoxy-2-nonenal binds to and results in increased lipidation of AGT protein modified form |
CTD |
PMID:26111765 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
affects reduction increases reduction |
ISO |
AKR1B1 protein affects the reduction of 4-hydroxy-2-octenal AKR1B1 protein results in increased reduction of 4-hydroxy-2-octenal |
CTD |
PMID:9890881 PMID:11306073 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
4-hydroxy-2-hexenal results in increased expression of ACTA2 mRNA |
CTD |
PMID:28760545 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases reduction affects reduction |
ISO |
AKR1B1 protein results in increased reduction of 4-hydroxy-2-hexenal AKR1B1 protein affects the reduction of 4-hydroxy-2-hexenal |
CTD |
PMID:9890881 PMID:11306073 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Casp3 |
caspase 3 |
increases activity |
EXP |
4-hydroxy-2-hexenal results in increased activity of CASP3 protein |
CTD |
PMID:20619253 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cdh1 |
cadherin 1 |
decreases expression |
ISO |
4-hydroxy-2-hexenal results in decreased expression of CDH1 mRNA |
CTD |
PMID:28760545 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression |
ISO |
4-hydroxy-2-hexenal results in increased expression of MMP9 mRNA; 4-hydroxy-2-hexenal results in increased expression of MMP9 protein |
CTD |
PMID:28760545 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
multiple interactions |
EXP |
[PTGR1 protein co-treated with NADP] affects the reduction of 4-hydroxy-2-hexenal |
CTD |
PMID:11524419 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Slc25a4 |
solute carrier family 25 member 4 |
affects binding |
EXP |
SLC25A4 protein binds to 4-hydroxy-2-hexenal |
CTD |
PMID:17385840 |
|
NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733
|
|
G |
Vim |
vimentin |
increases expression |
ISO |
4-hydroxy-2-hexenal results in increased expression of VIM mRNA |
CTD |
PMID:28760545 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ABCA1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects binding increases expression multiple interactions |
ISO |
4-hydroxy-2-nonenal binds to ABCC1 protein 4-hydroxy-2-nonenal results in increased expression of ABCC1 mRNA [GSTM1 protein co-treated with ABCC1 protein] results in increased susceptibility to 4-hydroxy-2-nonenal |
CTD |
PMID:15672542 PMID:19191707 PMID:21925487 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export multiple interactions |
EXP ISO |
ABCC2 protein affects the export of 4-hydroxy-2-nonenal metabolite 4-hydroxy-2-nonenal inhibits the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein]; Ascorbic Acid inhibits the reaction [4-hydroxy-2-nonenal inhibits the reaction [ABCC2 protein results in increased transport of 5(6)-carboxy-2',7'-dichlorofluorescein]] |
CTD |
PMID:12623073 PMID:19326901 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
affects binding |
EXP |
4-hydroxy-2-nonenal binds to ACTA1 protein |
CTD |
PMID:15886073 |
|
NCBI chr19:51,883,709...51,886,735
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Actb |
actin, beta |
affects binding |
ISO |
ACTB protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Actn1 |
actinin, alpha 1 |
affects binding |
ISO |
ACTN1 protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251
|
|
G |
Actn4 |
actinin alpha 4 |
affects binding |
ISO |
ACTN4 protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847
|
|
G |
Adh7 |
alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ADH7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:226,748,724...226,763,183
Ensembl chr 2:226,741,788...226,763,182
|
|
G |
Adi1 |
acireductone dioxygenase 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ADI1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:45,306,841...45,313,842
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ADORA1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adora2b |
adenosine A2B receptor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ADORA2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:46,940,394...46,956,772
Ensembl chr10:46,940,384...46,956,772
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ADRB2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AGO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AGO3 mRNA 4-hydroxy-2-nonenal results in increased expression of AGO3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230
|
|
G |
Agrn |
agrin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AGRN mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
|
|
G |
Agt |
angiotensinogen |
affects binding multiple interactions |
ISO |
4-hydroxy-2-nonenal binds to AGT protein modified form; AGT protein modified form binds to 4-hydroxy-2-nonenal 4-hydroxy-2-nonenal binds to and results in increased lipidation of AGT protein modified form; [AGT protein modified form results in increased chemical synthesis of Lipid Peroxides] which results in increased abundance of 4-hydroxy-2-nonenal; [Ascorbic Acid co-treated with Copper Sulfate] promotes the reaction [AGT protein modified form results in increased chemical synthesis of [4-hydroxy-2-nonenal binds to AGT protein modified form]]; AGT protein modified form results in increased chemical synthesis of [4-hydroxy-2-nonenal binds to AGT protein modified form]; Losartan inhibits the reaction [[AGT protein modified form co-treated with Ascorbic Acid co-treated with Copper Sulfate] results in increased chemical synthesis of [4-hydroxy-2-nonenal binds to AGT protein modified form]] |
CTD |
PMID:20977208 PMID:26111765 PMID:31144504 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahsa2 |
activator of HSP90 ATPase homolog 2 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of AHSA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:97,476,304...97,485,725
Ensembl chr14:97,476,817...97,485,657
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of AIFM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akna |
AT-hook transcription factor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AKNA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017
|
|
G |
Akr1a1 |
aldo-keto reductase family 1 member A1 |
increases reduction increases expression |
ISO |
AKR1A1 protein results in increased reduction of 4-hydroxy-2-nonenal 4-hydroxy-2-nonenal results in increased expression of AKR1A1 mRNA |
CTD |
PMID:10510318 PMID:19191707 |
|
NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
affects reduction increases reduction |
ISO |
AKR1B1 protein affects the reduction of 4-hydroxy-2-nonenal AKR1B1 protein results in increased reduction of 4-hydroxy-2-nonenal; AKR1B1 protein results in increased reduction of 4-hydroxy-2-nonenal metabolite |
CTD |
PMID:9890881 PMID:10510318 PMID:11306073 PMID:21329684 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
increases reduction multiple interactions increases metabolic processing |
ISO |
AKR1B10 protein results in increased reduction of 4-hydroxy-2-nonenal Oleanolic Acid inhibits the reaction [AKR1B10 protein results in increased metabolism of 4-hydroxy-2-nonenal] |
CTD |
PMID:19013440 PMID:21329684 PMID:27417252 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
increases expression increases response to substance multiple interactions |
ISO |
4-hydroxy-2-nonenal results in increased expression of AKR1C3 mRNA; 4-hydroxy-2-nonenal results in increased expression of AKR1C3 protein AKR1C3 mutant form results in increased susceptibility to 4-hydroxy-2-nonenal 7-hydroxycoumarin inhibits the reaction [AKR1C3 mutant form results in increased susceptibility to 4-hydroxy-2-nonenal] |
CTD |
PMID:22964423 PMID:30849339 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akr7a2 |
aldo-keto reductase family 7, member A2 |
decreases response to substance affects response to substance increases response to substance multiple interactions increases expression |
ISO |
AKR7A2 protein results in decreased susceptibility to 4-hydroxy-2-nonenal AKR7A2 protein affects the susceptibility to 4-hydroxy-2-nonenal AKR7A2 mutant form results in increased susceptibility to 4-hydroxy-2-nonenal 7-hydroxycoumarin affects the reaction [AKR7A2 mutant form results in increased susceptibility to 4-hydroxy-2-nonenal]; AKR7A2 protein affects the reaction [NFE2L2 protein affects the susceptibility to 4-hydroxy-2-nonenal] 4-hydroxy-2-nonenal results in increased expression of AKR7A2 mRNA; 4-hydroxy-2-nonenal results in increased expression of AKR7A2 protein |
CTD |
PMID:22001351 PMID:22964423 PMID:30849339 |
|
NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
affects response to substance decreases phosphorylation increases activity multiple interactions |
EXP ISO |
AKT1 protein affects the susceptibility to 4-hydroxy-2-nonenal 4-hydroxy-2-nonenal results in decreased phosphorylation of AKT1 protein 4-hydroxy-2-nonenal results in increased activity of AKT1 protein AKT1 protein affects the reaction [4-hydroxy-2-nonenal results in increased expression of MMP2 protein] |
CTD |
PMID:18805481 PMID:23845594 PMID:24825450 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CCND3 protein; [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CDK6 protein; [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of RB1 protein modified form; [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased secretion of IFNG protein; [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased secretion of IL6 protein; [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased secretion of TNF protein; [ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene; sulforaphane inhibits the reaction [[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CCND3 protein]; sulforaphane inhibits the reaction [[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CDK6 protein]; sulforaphane inhibits the reaction [[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased secretion of IFNG protein]; sulforaphane inhibits the reaction [[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased secretion of IL6 protein]; sulforaphane inhibits the reaction [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] |
CTD |
PMID:33007382 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
increases metabolic processing increases oxidation multiple interactions |
ISO |
ALDH1A1 protein results in increased metabolism of 4-hydroxy-2-nonenal ALDH1A1 protein results in increased oxidation of 4-hydroxy-2-nonenal [APC protein mutant form results in increased expression of ALDH1A1 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal |
CTD |
PMID:21256123 PMID:21967605 PMID:22339434 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
multiple interactions increases oxidation |
ISO |
[APC protein mutant form results in increased expression of ALDH2 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal ALDH2 protein results in increased oxidation of 4-hydroxy-2-nonenal 4-hydroxy-2-nonenal binds to and results in decreased activity of ALDH2 protein; ALDH2 protein inhibits the reaction [Rotenone results in increased abundance of 4-hydroxy-2-nonenal] |
CTD |
PMID:21967605 PMID:22339434 PMID:25263579 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh3a1 |
aldehyde dehydrogenase 3 family, member A1 |
decreases response to substance increases oxidation multiple interactions increases metabolic processing affects response to substance affects metabolic processing |
ISO EXP |
ALDH3A1 protein results in decreased susceptibility to 4-hydroxy-2-nonenal ALDH3A1 protein results in increased oxidation of 4-hydroxy-2-nonenal [APC protein mutant form results in increased expression of ALDH3A1 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal ALDH3A1 protein results in increased metabolism of 4-hydroxy-2-nonenal ALDH3A1 protein affects the susceptibility to 4-hydroxy-2-nonenal ALDH3A1 protein affects the metabolism of 4-hydroxy-2-nonenal |
CTD |
PMID:11018474 PMID:11306050 PMID:15905174 PMID:21256123 PMID:21967605 PMID:22339434 More...
|
|
NCBI chr10:45,892,993...45,902,680
Ensembl chr10:45,892,924...45,902,681
|
|
G |
Aldh3b1 |
aldehyde dehydrogenase 3 family, member B1 |
affects binding decreases response to substance |
ISO |
4-hydroxy-2-nonenal binds to ALDH3B1 protein ALDH3B1 protein results in decreased susceptibility to 4-hydroxy-2-nonenal |
CTD |
PMID:20699116 |
|
NCBI chr 1:201,145,309...201,162,675
Ensembl chr 1:201,145,309...201,163,921
|
|
G |
Aldh6a1 |
aldehyde dehydrogenase 6 family, member A1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ALDH6A1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
|
|
G |
Aldh7a1 |
aldehyde dehydrogenase 7 family, member A1 |
increases metabolic processing decreases response to substance |
ISO |
ALDH7A1 protein results in increased metabolism of 4-hydroxy-2-nonenal ALDH7A1 protein results in decreased susceptibility to 4-hydroxy-2-nonenal |
CTD |
PMID:21338592 |
|
NCBI chr18:50,003,242...50,042,193
Ensembl chr18:50,009,934...50,042,193
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
affects binding |
ISO |
ALDOA protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to ALDOA protein] |
CTD |
PMID:20889679 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 mutant form inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of MMP9 protein] |
CTD |
PMID:19837106 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ALOX5AP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Alpk1 |
alpha-kinase 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ALPK1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:216,126,939...216,247,180
Ensembl chr 2:216,128,825...216,247,157
|
|
G |
Als2 |
alsin Rho guanine nucleotide exchange factor ALS2 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ALS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:60,613,182...60,686,394
Ensembl chr 9:60,613,167...60,670,737
|
|
G |
Amph |
amphiphysin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AMPH mRNA |
CTD |
PMID:12419474 |
|
NCBI chr17:45,739,385...45,982,905
Ensembl chr17:45,739,395...45,983,315
|
|
G |
Anln |
anillin, actin binding protein |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ANLN mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ANP32A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:62,829,099...62,865,443
Ensembl chr 8:62,827,456...62,865,443
|
|
G |
Aoah |
acyloxyacyl hydrolase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AOAH mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:43,808,110...44,049,458
Ensembl chr17:43,809,638...44,049,148
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of AOX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Ap1s3 |
adaptor related protein complex 1 subunit sigma 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AP1S3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:80,950,402...81,009,889
Ensembl chr 9:80,950,715...81,009,798
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression affects oxidation affects response to substance multiple interactions |
ISO |
4-hydroxy-2-nonenal results in decreased expression of APC mRNA APC protein affects the oxidation of 4-hydroxy-2-nonenal APC protein affects the susceptibility to 4-hydroxy-2-nonenal [APC protein affects the oxidation of 4-hydroxy-2-nonenal] which affects the abundance of 4-hydroxynonenoic acid; [APC protein mutant form results in increased expression of ALDH1A1 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal; [APC protein mutant form results in increased expression of ALDH2 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal; [APC protein mutant form results in increased expression of ALDH3A1 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal; [APC protein mutant form results in increased expression of GSTA4 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal; [APC protein mutant form results in increased expression of SLC7A11 mRNA] which affects the metabolism of 4-hydroxy-2-nonenal |
CTD |
PMID:12419474 PMID:21967605 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apex1 |
apurinic/apyrimidinic endodeoxyribonuclease 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of APEX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785
|
|
G |
Apoa1 |
apolipoprotein A1 |
affects binding |
ISO |
4-hydroxy-2-nonenal binds to APOA1 protein |
CTD |
PMID:18778096 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apod |
apolipoprotein D |
decreases abundance |
ISO |
APOD protein results in decreased abundance of 4-hydroxy-2-nonenal |
CTD |
PMID:28182653 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
App |
amyloid beta precursor protein |
decreases expression multiple interactions |
ISO |
4-hydroxy-2-nonenal results in decreased expression of APP mRNA [[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal; [APP protein modified form inhibits the reaction [[Copper co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide]] which results in increased chemical synthesis of 4-hydroxy-2-nonenal; Deferoxamine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]; Edetic Acid inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal]; Trientine inhibits the reaction [[[[APP protein modified form binds to Copper] which co-treated with Ascorbic Acid] results in increased oxidation of phosphatidylcholine hydroperoxide] which results in increased chemical synthesis of 4-hydroxy-2-nonenal] |
CTD |
PMID:12419474 PMID:17964426 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arhgap11a |
Rho GTPase activating protein 11A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ARHGAP11A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:100,590,865...100,607,146
Ensembl chr 3:100,590,865...100,607,559
|
|
G |
Arhgap22 |
Rho GTPase activating protein 22 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ARHGAP22 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:8,473,806...8,631,552
Ensembl chr16:8,476,306...8,631,548
|
|
G |
Arhgap27 |
Rho GTPase activating protein 27 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ARHGAP27 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:88,280,470...88,313,225
Ensembl chr10:88,280,455...88,313,185
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ARHGAP5 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 6:69,975,904...70,039,299
Ensembl chr 6:69,976,214...70,037,660
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:12419474 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgef3 |
Rho guanine nucleotide exchange factor 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ARHGEF3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:2,301,573...2,581,951
Ensembl chr16:2,300,138...2,581,945
|
|
G |
Arid5a |
AT-rich interaction domain 5A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ARID5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:38,534,612...38,549,467
Ensembl chr 9:38,534,590...38,547,597
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ARRDC3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:11,137,464...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Asf1b |
anti-silencing function 1B histone chaperone |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ASF1B mRNA 4-hydroxy-2-nonenal results in increased expression of ASF1B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549
|
|
G |
Aspm |
assembly factor for spindle microtubules |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ASPM mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755
|
|
G |
Atad5 |
ATPase family, AAA domain containing 5 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ATAD5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:65,070,682...65,118,489
Ensembl chr10:65,070,689...65,117,845
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ATF3 protein |
CTD |
PMID:19041636 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
EXP |
4-hydroxy-2-nonenal results in increased expression of ATF4 mRNA; 4-hydroxy-2-nonenal results in increased expression of ATF4 protein Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of ATF4 protein] |
CTD |
PMID:24291486 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
increases expression multiple interactions |
EXP |
4-hydroxy-2-nonenal results in increased expression of ATF6 protein modified form Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of ATF6 protein modified form] |
CTD |
PMID:24291486 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ATG5 mRNA |
CTD |
PMID:35550146 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ATG7 mRNA |
CTD |
PMID:35550146 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atm |
ATM serine/threonine kinase |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ATM mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1b3 |
ATPase Na+/K+ transporting subunit beta 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ATP1B3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
affects binding |
ISO |
4-hydroxy-2-nonenal binds to ATP5F1A protein |
CTD |
PMID:19374891 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ATP6V1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atr |
ATR serine/threonine kinase |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ATR mRNA 4-hydroxy-2-nonenal results in increased expression of ATR mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136
|
|
G |
Avil |
advillin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AVIL mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:62,825,459...62,844,103
Ensembl chr 7:62,826,025...62,844,071
|
|
G |
B2m |
beta-2 microglobulin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of B2M mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
|
|
G |
Babam2 |
BRISC and BRCA1 A complex member 2 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BABAM2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:24,369,021...24,788,416
Ensembl chr 6:24,369,022...24,833,951
|
|
G |
Bad |
BCL2-associated agonist of cell death |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BAD mRNA 4-hydroxy-2-nonenal results in increased expression of BAD protein |
CTD |
PMID:12419474 PMID:24825450 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Batf2 |
basic leucine zipper ATF-like transcription factor 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BATF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:203,467,291...203,479,428
Ensembl chr 1:203,468,097...203,475,889
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression increases expression |
ISO EXP |
4-hydroxy-2-nonenal results in decreased expression of BAX mRNA 4-hydroxy-2-nonenal results in increased expression of BAX protein |
CTD |
PMID:12419474 PMID:15607904 PMID:21187080 PMID:24825450 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
multiple interactions increases expression |
EXP |
4-phenylbutylamine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of BBC3 mRNA]; Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of BBC3 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bbx |
BBX high mobility group box domain containing |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BBX mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:50,381,249...50,628,934
Ensembl chr11:50,381,247...50,623,251
|
|
G |
Bcar3 |
BCAR3 adaptor protein, NSP family member |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BCAR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BCL2A1B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BCL2L1 mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BCL2L11 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BCL3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression multiple interactions |
EXP |
4-hydroxy-2-nonenal results in decreased expression of BDNF mRNA CREBBP protein inhibits the reaction [4-hydroxy-2-nonenal results in decreased expression of BDNF mRNA] |
CTD |
PMID:16337876 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bgn |
biglycan |
multiple interactions |
ISO |
[[BGN mRNA alternative form binds to OTUB1 protein] which binds to and results in decreased ubiquitination of and results in increased stability of SLC7A11 protein] which results in decreased abundance of 4-hydroxy-2-nonenal |
CTD |
PMID:35234341 |
|
NCBI chr X:151,197,296...151,209,458
Ensembl chr X:151,197,273...151,209,461
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BHLHE40 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bhlhe41 |
basic helix-loop-helix family, member e41 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BHLHE41 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:178,834,264...178,838,618
Ensembl chr 4:178,834,271...178,838,468
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BID mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
increases expression decreases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BIRC5 mRNA 4-hydroxy-2-nonenal results in decreased expression of BIRC5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Blm |
BLM RecQ like helicase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BLM mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312
|
|
G |
Blvrb |
biliverdin reductase B |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BLVRB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
|
|
G |
Bmp1 |
bone morphogenetic protein 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BMP1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr15:45,551,603...45,595,862
Ensembl chr15:45,551,603...45,595,776
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BNIP3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Braf |
B-Raf proto-oncogene, serine/threonine kinase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BRAF mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BUB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
Bub1b |
BUB1 mitotic checkpoint serine/threonine kinase B |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of BUB1B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547
|
|
G |
Bzw1 |
basic leucine zipper and W2 domains 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of BZW1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:59,930,672...59,944,468
Ensembl chr 9:59,930,744...59,944,430
|
|
G |
C5ar1 |
complement C5a receptor 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of C5AR1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:76,948,622...76,959,826
|
|
G |
Cacna1a |
calcium voltage-gated channel subunit alpha1 A |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CACNA1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:23,520,741...23,819,971
Ensembl chr19:23,520,741...23,823,225
|
|
G |
Cadps |
calcium dependent secretion activator |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CADPS mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:12,289,803...12,742,786
Ensembl chr15:12,290,262...12,742,779
|
|
G |
Calca |
calcitonin-related polypeptide alpha |
increases secretion |
EXP |
4-hydroxy-2-nonenal results in increased secretion of CALCA protein |
CTD |
PMID:17684094 |
|
NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105
|
|
G |
Calcoco1 |
calcium binding and coiled coil domain 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CALCOCO1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:133,834,705...133,849,515
Ensembl chr 7:133,834,707...133,849,422
|
|
G |
Calr3 |
calreticulin 3 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CALR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:17,396,064...17,423,166
Ensembl chr16:17,396,247...17,423,015
|
|
G |
Camk1d |
calcium/calmodulin-dependent protein kinase ID |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CAMK1D mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556
|
|
G |
Cap1 |
cyclase associated actin cytoskeleton regulatory protein 1 |
affects binding |
ISO |
CAP1 protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 5:135,142,108...135,168,885
Ensembl chr 5:135,142,112...135,168,769
|
|
G |
Capn2 |
calpain 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CAPN2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:94,150,244...94,200,969
Ensembl chr13:94,150,240...94,200,969
|
|
G |
Capns1 |
calpain, small subunit 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CAPNS1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:85,444,613...85,454,861
Ensembl chr 1:85,444,608...85,454,795
|
|
G |
Capzb |
capping actin protein of muscle Z-line subunit beta |
affects binding |
ISO |
CAPZB protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 5:151,435,600...151,535,409
Ensembl chr 5:151,434,871...151,535,409
|
|
G |
Car12 |
carbonic anhydrase 12 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CAR12 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Car2 |
carbonic anhydrase 2 |
affects binding |
ISO |
CA2 protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Carhsp1 |
calcium regulated heat stable protein 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CARHSP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:6,946,036...6,960,556
Ensembl chr10:6,946,959...7,020,019
|
|
G |
Cask |
calcium/calmodulin dependent serine protein kinase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CASK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr X:8,899,500...9,243,014
Ensembl chr X:8,899,833...9,238,694
|
|
G |
Casp1 |
caspase 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CASP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO EXP |
4-hydroxy-2-nonenal results in increased cleavage of and results in increased activity of CASP3 protein; pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP3 protein]; resveratrol inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP3 protein] 4-hydroxy-2-nonenal results in increased cleavage of CASP3 protein Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP3 protein] |
CTD |
PMID:11488593 PMID:16322078 PMID:16337876 PMID:17263905 PMID:19326901 PMID:20114059 PMID:21187080 PMID:24291486 PMID:24825450 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CASP4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CASP7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CASP8 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
4-hydroxy-2-nonenal results in increased activity of CASP9 protein pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP9 protein]; resveratrol inhibits the reaction [4-hydroxy-2-nonenal results in increased activity of CASP9 protein] |
CTD |
PMID:16322078 PMID:17263905 PMID:21187080 PMID:24825450 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CAT mRNA |
CTD |
PMID:19191707 PMID:24423726 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cblb |
Cbl proto-oncogene B |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CBLB mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL17 mRNA 4-hydroxy-2-nonenal results in increased expression of CCL17 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:10,202,128...10,203,903
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL22 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:10,257,602...10,264,373
Ensembl chr19:10,257,601...10,264,400
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions decreases expression |
ISO |
4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CCL5 protein] 4-hydroxy-2-nonenal results in decreased expression of CCL5 mRNA |
CTD |
PMID:19191707 PMID:19627980 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL7 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccl9 |
C-C motif chemokine ligand 9 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCL6 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:68,366,486...68,371,408
Ensembl chr10:68,366,487...68,371,369
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCNA2 mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCNB1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of CCND1] 4-hydroxy-2-nonenal results in increased expression of CCND1; 4-hydroxy-2-nonenal results in increased expression of CCND1 mRNA |
CTD |
PMID:16328008 PMID:19191707 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCND2 protein |
CTD |
PMID:15607904 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CCND3 protein; sulforaphane inhibits the reaction [[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CCND3 protein] |
CTD |
PMID:33007382 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccnf |
cyclin F |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCNF mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CCNG1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Ccng2 |
cyclin G2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCNG2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
|
|
G |
Ccnk |
cyclin K |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCNK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 6:127,090,115...127,113,195
Ensembl chr 6:127,090,569...127,113,191
|
|
G |
Ccnt1 |
cyclin T1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCNT1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CCR1 mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CD14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd300a |
Cd300a molecule |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CD300A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:99,929,801...99,942,674
Ensembl chr10:99,929,801...99,942,674
|
|
G |
Cd300lb |
CD300 molecule-like family member b |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CD300LB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:99,964,801...99,974,790
Ensembl chr10:99,964,801...99,974,790
|
|
G |
Cd300lf |
Cd300 molecule-like family member F |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CD300LF mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:100,359,942...100,376,130
Ensembl chr10:100,359,943...100,376,041
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CD36 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd40 |
CD40 molecule |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CD40 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd44 |
CD44 molecule |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CD44 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd47 |
Cd47 molecule |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CD47 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:50,906,052...50,970,000
Ensembl chr11:50,906,177...50,969,425
|
|
G |
Cd83 |
CD83 molecule |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CD83 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CD86 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc20 |
cell division cycle 20 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDC20 mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 5:131,966,203...131,970,406
Ensembl chr 5:131,966,215...131,970,512
|
|
G |
Cdc25a |
cell division cycle 25A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDC25A mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
|
|
G |
Cdc25c |
cell division cycle 25C |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDC25C mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdca2 |
cell division cycle associated 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDCA2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
[procymidone co-treated with iprodione co-treated with cyprodinil co-treated with fludioxonil co-treated with cyhalothrin co-treated with 4-hydroxy-2-nonenal] results in decreased expression of CDH1 protein |
CTD |
PMID:34503147 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDH2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh3 |
cadherin 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDH3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr19:34,393,596...34,444,084
Ensembl chr19:34,393,727...34,444,084
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
4-hydroxy-2-nonenal binds to and results in increased alkylation of and results in decreased activity of CDK2 protein |
CTD |
PMID:26910110 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
increases expression multiple interactions |
ISO |
4-hydroxy-2-nonenal results in increased expression of CDK6 mRNA [[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CDK6 protein; sulforaphane inhibits the reaction [[[ALB protein binds to 4-hydroxy-2-nonenal] which results in increased susceptibility to Trichloroethylene] which results in increased expression of CDK6 protein] |
CTD |
PMID:19191707 PMID:33007382 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdk9 |
cyclin-dependent kinase 9 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDK9 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CDKN1A protein |
CTD |
PMID:15607904 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDKN1C mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CDKN2D mRNA |
CTD |
PMID:12419474 PMID:19191707 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CEBPA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cenpa |
centromere protein A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CENPA mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675
|
|
G |
Cep290 |
centrosomal protein 290 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CEP290 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:35,310,071...35,399,388
Ensembl chr 7:35,310,199...35,399,392
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity |
ISO |
4-hydroxy-2-nonenal results in decreased activity of CES1 protein |
CTD |
PMID:21878322 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases activity |
ISO |
4-hydroxy-2-nonenal results in increased activity of CES2 protein |
CTD |
PMID:21878322 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cfb |
complement factor B |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CFB mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505
|
|
G |
Cfl1 |
cofilin 1 |
affects binding |
ISO |
CFL1 protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587
|
|
G |
Chek1 |
checkpoint kinase 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CHEK1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chml |
CHM like Rab escort protein |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CHML mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:87,609,647...87,619,868
Ensembl chr13:87,589,298...87,619,862
|
|
G |
Cilk1 |
ciliogenesis associated kinase 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CILK1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CISH mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:107,972,306...107,977,254
Ensembl chr 8:107,972,306...107,977,250
|
|
G |
Cks1b |
CDC28 protein kinase regulatory subunit 1B |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CKS1B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636
|
|
G |
Cks2 |
CDC28 protein kinase regulatory subunit 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CKS2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:13,570,611...13,575,770
|
|
G |
Cldn11 |
claudin 11 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CLDN11 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Clec12a |
C-type lectin domain family 12, member A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CLEC12A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:162,798,125...162,816,757
Ensembl chr 4:162,798,125...162,816,753
|
|
G |
Clec4a |
C-type lectin domain family 4, member A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CLEC4N mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:156,340,439...156,434,212
Ensembl chr 4:156,414,688...156,432,402
|
|
G |
Clec4d |
C-type lectin domain family 4, member D |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CLEC4D mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:156,589,591...156,599,279
Ensembl chr 4:156,589,792...156,598,848
|
|
G |
Clec5a |
C-type lectin domain containing 5A |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CLEC5A mRNA 4-hydroxy-2-nonenal results in increased expression of CLEC5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:69,407,125...69,416,872
Ensembl chr 4:69,407,835...69,416,859
|
|
G |
Clk3 |
CDC-like kinase 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CLK3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:58,152,155...58,167,196
Ensembl chr 8:58,152,155...58,168,181
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of COL1A1 mRNA; 4-hydroxy-2-nonenal results in increased expression of COL1A1 protein |
CTD |
PMID:14672615 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Comt |
catechol-O-methyltransferase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of COMT mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642
|
|
G |
Cp |
ceruloplasmin |
decreases expression affects abundance |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CP mRNA CP protein affects the abundance of 4-hydroxy-2-nonenal |
CTD |
PMID:12572680 PMID:19191707 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Cpe |
carboxypeptidase E |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CPE mRNA |
CTD |
PMID:12419474 |
|
NCBI chr16:25,030,276...25,142,231
Ensembl chr16:25,030,276...25,142,233
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
decreases expression increases phosphorylation |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CREB1 mRNA 4-hydroxy-2-nonenal results in increased phosphorylation of CREB1 protein |
CTD |
PMID:12419474 PMID:16337876 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
EXP |
CREBBP protein inhibits the reaction [4-hydroxy-2-nonenal results in decreased expression of BDNF mRNA] |
CTD |
PMID:16337876 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Creg1 |
cellular repressor of E1A-stimulated genes 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CREG1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:78,019,814...78,032,310
Ensembl chr13:78,019,843...78,032,308
|
|
G |
Crot |
carnitine O-octanoyltransferase |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CROT mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Cry1 |
cryptochrome circadian regulator 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CRY1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091
|
|
G |
Cry2 |
cryptochrome circadian regulator 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CRY2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 3:78,374,995...78,405,001
Ensembl chr 3:78,374,995...78,404,965
|
|
G |
Cryz |
crystallin zeta |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CRYZ mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:243,552,037...243,580,369
Ensembl chr 2:243,552,119...243,579,758
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CSF1R mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2 |
colony stimulating factor 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CSF2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Csf3 |
colony stimulating factor 3 |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CSF3 mRNA 4-hydroxy-2-nonenal results in increased expression of CSF3 mRNA; 4-hydroxy-2-nonenal results in increased expression of CSF3 protein |
CTD |
PMID:19191707 |
|
NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
|
|
G |
Csnk1g2 |
casein kinase 1, gamma 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CSNK1G2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 7:9,076,739...9,095,082
Ensembl chr 7:9,076,740...9,095,052
|
|
G |
Csrnp1 |
cysteine and serine rich nuclear protein 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of AXUD1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183
|
|
G |
Ctnnb1 |
catenin beta 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CTNNB1 mRNA; 4-hydroxy-2-nonenal results in decreased expression of CTNNB1 protein |
CTD |
PMID:12419474 PMID:24825450 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsd |
cathepsin D |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of CTSD mRNA]; TFEB protein affects the reaction [4-hydroxy-2-nonenal results in increased expression of CTSD mRNA] |
CTD |
PMID:35550146 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CTSL mRNA |
CTD |
PMID:12419474 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cttn |
cortactin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CTTN mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164
|
|
G |
Cux1 |
cut-like homeobox 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CUX1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr12:20,107,062...20,425,868
Ensembl chr12:20,107,311...20,425,866
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 mRNA]; 4-hydroxy-2-nonenal inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL10 protein] |
CTD |
PMID:19627980 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl14 |
C-X-C motif chemokine ligand 14 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CXCL14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:8,317,930...8,325,956
Ensembl chr17:8,317,933...8,324,839
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CXCL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr4 |
C-X-C motif chemokine receptor 4 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of CXCR4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
|
|
G |
Cybb |
cytochrome b-245 beta chain |
increases abundance |
ISO |
CYBB protein results in increased abundance of 4-hydroxy-2-nonenal |
CTD |
PMID:19417757 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization multiple interactions |
ISO EXP |
4-hydroxy-2-nonenal affects the localization of CYCS protein pyrazolanthrone inhibits the reaction [4-hydroxy-2-nonenal affects the localization of CYCS protein]; resveratrol inhibits the reaction [4-hydroxy-2-nonenal affects the localization of CYCS protein] |
CTD |
PMID:16322078 PMID:17263905 PMID:21187080 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[CYP1A2 protein results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; CYP1A2 protein results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal |
CTD |
PMID:21766881 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
multiple interactions |
ISO |
[CYP2B6 protein results in increased oxidation of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 4-hydroxy-2-nonenoic acid; [CYP2B6 protein results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; CYP2B6 protein results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal |
CTD |
PMID:21766881 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
multiple interactions |
ISO |
[CYP2C29 protein results in increased oxidation of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 4-hydroxy-2-nonenoic acid; [CYP2C29 protein results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; CYP2C29 protein results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal |
CTD |
PMID:21766881 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
[CYP2J2 protein results in increased oxidation of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 4-hydroxy-2-nonenoic acid; [CYP2J2 protein results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; CYP2J2 protein results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal |
CTD |
PMID:21766881 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[[CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 1,4-dihydroxy-2-nonene; [CYP3A4 protein co-treated with Oxygen co-treated with NADP] results in increased reduction of and results in increased oxidation of 4-hydroxy-2-nonenal; [CYP3A4 protein results in increased oxidation of 4-hydroxy-2-nonenal] which results in increased chemical synthesis of 4-hydroxy-2-nonenoic acid |
CTD |
PMID:21766881 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CYSLTR1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cyth4 |
cytohesin 4 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of CYTH4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:110,152,232...110,176,726
Ensembl chr 7:110,152,272...110,176,741
|
|
G |
Dap |
death-associated protein |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of DAP mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752
|
|
G |
Dapk1 |
death associated protein kinase 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DAPK1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr17:3,930,223...4,090,991
Ensembl chr17:3,930,213...4,090,991
|
|
G |
Dbf4 |
DBF4-CDC7 kinase regulatory subunit |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DBF4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066
|
|
G |
Dcn |
decorin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DCN mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
EXP |
4-hydroxy-2-nonenal results in increased expression of DDIT3 mRNA; 4-hydroxy-2-nonenal results in increased expression of DDIT3 protein Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of DDIT3 mRNA] |
CTD |
PMID:24291486 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DDIT4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddr2 |
discoidin domain receptor tyrosine kinase 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DDR2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr13:82,193,623...82,318,229
Ensembl chr13:82,195,463...82,317,363
|
|
G |
Denr |
density regulated reinitiation and release factor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DENR mRNA |
CTD |
PMID:19191707 |
|
NCBI chr12:32,662,512...32,685,283
Ensembl chr12:32,662,516...32,683,843
|
|
G |
Dffa |
DNA fragmentation factor subunit alpha |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DFFA mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:159,540,715...159,553,639
Ensembl chr 5:159,540,715...159,553,633
|
|
G |
Dffb |
DNA fragmentation factor subunit beta |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DFFB mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:164,522,446...164,534,733
Ensembl chr 5:164,522,463...164,534,628
|
|
G |
Dgkh |
diacylglycerol kinase, eta |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DGKH mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:53,981,079...54,150,470
Ensembl chr15:53,991,481...54,150,706
|
|
G |
Dhx58 |
DEXH-box helicase 58 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DHX58 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:85,620,352...85,631,776
Ensembl chr10:85,620,357...85,631,525
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DIO2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dlgap5 |
DLG associated protein 5 |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DLGAP5 mRNA 4-hydroxy-2-nonenal results in increased expression of DLGAP5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
|
|
G |
Dnajb4 |
DnaJ heat shock protein family (Hsp40) member B4 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of DNAJB4 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:241,129,346...241,159,272
Ensembl chr 2:241,130,340...241,159,089
|
|
G |
Dnajc3 |
DnaJ heat shock protein family (Hsp40) member C3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DNAJC3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr15:96,025,605...96,068,585
Ensembl chr15:96,025,624...96,065,181
|
|
G |
Dnase2 |
deoxyribonuclease 2, lysosomal |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of DNASE2A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:23,244,656...23,247,376
Ensembl chr19:23,244,664...23,247,376
|
|
G |
Dnph1 |
2'-deoxynucleoside 5'-phosphate N-hydrolase 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DNPH1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:14,481,296...14,484,034
Ensembl chr 9:14,481,066...14,484,022
|
|
G |
Dpysl2 |
dihydropyrimidinase-like 2 |
affects binding |
ISO |
4-hydroxy-2-nonenal binds to DPYSL2 protein |
CTD |
PMID:19374891 |
|
NCBI chr15:41,005,551...41,111,724
Ensembl chr15:41,005,551...41,111,829
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
EXP |
4-hydroxy-2-nonenal results in decreased expression of DRD2 protein |
CTD |
PMID:20570720 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Dst |
dystonin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of DST mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
|
|
G |
Dynlt3 |
dynein light chain Tctex-type 3 |
affects binding |
ISO |
DYNLT3 protein binds to 4-hydroxy-2-nonenal |
CTD |
PMID:20043646 |
|
NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139
|
|
G |
E2f1 |
E2F transcription factor 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of E2F1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
E2f2 |
E2F transcription factor 2 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of E2F2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217
|
|
G |
E2f8 |
E2F transcription factor 8 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of E2F8 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098
|
|
G |
Echdc3 |
enoyl CoA hydratase domain containing 3 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of ECHDC3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:72,070,697...72,093,519
Ensembl chr17:72,070,668...72,093,516
|
|
G |
Edn1 |
endothelin 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EDN1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eef2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
4-hydroxy-2-nonenal results in decreased expression of EEF2 protein |
CTD |
PMID:16469450 |
|
NCBI chr 7:8,533,248...8,538,518
Ensembl chr 7:8,533,116...8,559,183
|
|
G |
Efna4 |
ephrin A4 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EFNA4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:174,748,729...174,752,979
Ensembl chr 2:174,748,724...174,752,979
|
|
G |
Eid3 |
EP300 interacting inhibitor of differentiation 3 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of EID3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:20,860,073...20,861,395
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation |
ISO |
4-hydroxy-2-nonenal results in increased phosphorylation of EIF2A protein |
CTD |
PMID:19041636 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Eif2ak2 |
eukaryotic translation initiation factor 2-alpha kinase 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EIF2AK2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 6:16,189,000...16,224,972
Ensembl chr 6:16,188,979...16,224,971
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases phosphorylation |
ISO |
4-hydroxy-2-nonenal results in increased phosphorylation of EIF2AK3 protein |
CTD |
PMID:19041636 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
EXP |
Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:24291486 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of EIF4E mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4e2 |
eukaryotic translation initiation factor 4E family member 2 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of EIF4E2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:87,886,126...87,914,470
Ensembl chr 9:87,878,085...87,914,482
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
increases phosphorylation |
EXP |
4-hydroxy-2-nonenal results in increased phosphorylation of EIF4EBP1 protein |
CTD |
PMID:9890986 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif5a |
eukaryotic translation initiation factor 5A |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of EIF5A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ELK1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Eloc |
elongin C |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ELOC mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:2,661,527...2,677,893
Ensembl chr 5:2,661,724...2,677,890
|
|
G |
Elp1 |
elongator acetyltransferase complex subunit 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ELP1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:71,453,338...71,505,833
Ensembl chr 5:71,456,310...71,505,762
|
|
G |
Eme1 |
essential meiotic structure-specific endonuclease 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EME1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435
|
|
G |
Eno1 |
enolase 1 |
affects binding |
ISO |
4-hydroxy-2-nonenal binds to ENO1 protein |
CTD |
PMID:19374891 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of EPHX1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Eps15 |
epidermal growth factor receptor pathway substrate 15 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EPS15 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221
|
|
G |
Eps8 |
EGFR pathway substrate 8, signaling adaptor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EPS8 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 4:170,388,378...170,486,873
Ensembl chr 4:170,388,378...170,486,873
|
|
G |
Epsti1 |
epithelial stromal interaction 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EPSTI1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr15:53,283,964...53,382,192
Ensembl chr15:53,284,216...53,382,191
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERBB2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERBB4 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERCC1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Ercc2 |
ERCC excision repair 2, TFIIH core complex helicase subunit |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERCC2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:79,033,342...79,047,102
Ensembl chr 1:79,033,326...79,047,102
|
|
G |
Ercc5 |
ERCC excision repair 5, endonuclease |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERCC5 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 9:46,309,477...46,354,478
Ensembl chr 9:46,309,389...46,354,472
|
|
G |
Ercc6l |
ERCC excision repair 6 like, spindle assembly checkpoint helicase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERCC6L mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:67,245,414...67,261,222
Ensembl chr X:67,245,414...67,280,756
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ERN1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Espl1 |
extra spindle pole bodies like 1, separase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ESPL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ETS1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Ets2 |
ETS proto-oncogene 2, transcription factor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ETS2 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr11:35,021,536...35,038,322
Ensembl chr11:35,021,596...35,038,319
|
|
G |
Etv3 |
ETS variant transcription factor 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ETV3 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:172,965,461...172,980,320
Ensembl chr 2:172,965,588...172,980,314
|
|
G |
Etv6 |
ETS variant transcription factor 6 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of ETV6 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 4:166,849,031...167,085,211
Ensembl chr 4:166,847,686...167,084,992
|
|
G |
Ezr |
ezrin |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of EZR mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F10 |
coagulation factor X |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of F10 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F2r |
coagulation factor II (thrombin) receptor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of F2R mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:26,868,404...26,885,870
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of F3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fancd2 |
FA complementation group D2 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FANCD2 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fastk |
Fas-activated serine/threonine kinase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FASTK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
|
|
G |
Fbxl17 |
F-box and leucine-rich repeat protein 17 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FBXL17 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 9:102,780,573...103,206,978
Ensembl chr 9:102,782,440...103,208,950
|
|
G |
Fbxl20 |
F-box and leucine-rich repeat protein 20 |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FBXL20 mRNA 4-hydroxy-2-nonenal results in increased expression of FBXL20 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:83,080,568...83,143,680
Ensembl chr10:83,086,551...83,144,162
|
|
G |
Fbxo15 |
F-box protein 15 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FBXO15 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:78,319,577...78,634,695
Ensembl chr18:78,319,534...78,390,765
|
|
G |
Fbxo22 |
F-box protein 22 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FBXO22 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 8:55,579,906...55,595,981
Ensembl chr 8:55,579,891...55,596,148
|
|
G |
Fbxo30 |
F-box protein 30 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FBXO30 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:5,655,341...5,671,558
Ensembl chr 1:5,655,339...5,672,441
|
|
G |
Fbxo31 |
F-box protein 31 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FBXO31 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr19:49,624,813...49,656,052
Ensembl chr19:49,627,686...49,656,010
|
|
G |
Fbxo39 |
F-box protein 39 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FBXO39 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr10:56,929,699...56,934,911
Ensembl chr10:56,932,297...56,934,906
|
|
G |
Fbxo5 |
F-box protein 5 |
decreases expression increases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FBXO5 mRNA 4-hydroxy-2-nonenal results in increased expression of FBXO5 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437
|
|
G |
Fcgr1a |
Fc gamma receptor 1A |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FCGR1 mRNA; 4-hydroxy-2-nonenal results in decreased expression of FCGR1A mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 2:183,851,075...183,860,077
Ensembl chr 2:183,851,077...183,859,994
|
|
G |
Fcgr2b |
Fc gamma receptor 2B |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FCGR2B mRNA |
CTD |
PMID:19191707 |
|
NCBI chr13:83,191,253...83,207,778
Ensembl chr13:83,193,163...83,207,778
|
|
G |
Fech |
ferrochelatase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FECH mRNA |
CTD |
PMID:12419474 |
|
NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348
|
|
G |
Fem1c |
fem-1 homolog C |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FEM1C mRNA |
CTD |
PMID:19191707 |
|
NCBI chr18:39,232,900...39,258,692
Ensembl chr18:39,232,900...39,258,692
|
|
G |
Fen1 |
flap structure-specific endonuclease 1 |
increases expression decreases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FEN1 mRNA 4-hydroxy-2-nonenal results in decreased expression of FEN1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003
|
|
G |
Fgfr1 |
Fibroblast growth factor receptor 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FGFR1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr16:66,491,930...66,547,161
Ensembl chr16:66,494,042...66,547,350
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
increases expression decreases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FGR mRNA 4-hydroxy-2-nonenal results in decreased expression of FGR mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 5:145,189,814...145,219,571
Ensembl chr 5:145,189,841...145,217,326
|
|
G |
Fkbp14 |
FKBP prolyl isomerase 14 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FKBP14 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:83,705,531...83,721,515
Ensembl chr 4:83,705,652...83,721,528
|
|
G |
Fkbpl |
FKBP prolyl isomerase like |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of FKBPL mRNA |
CTD |
PMID:19191707 |
|
NCBI chr20:4,099,845...4,101,315
Ensembl chr20:4,099,806...4,101,368
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
decreases expression multiple interactions |
ISO EXP |
4-hydroxy-2-nonenal results in decreased expression of FOS mRNA 4-hydroxy-2-nonenal promotes the reaction [FOS protein binds to GGT1 promoter] resveratrol inhibits the reaction [4-hydroxy-2-nonenal results in decreased expression of FOS protein] |
CTD |
PMID:12419474 PMID:16195535 PMID:16322078 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosb |
FosB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
4-hydroxy-2-nonenal promotes the reaction [FOSB protein binds to GGT1 promoter] |
CTD |
PMID:16195535 |
|
NCBI chr 1:78,954,312...78,961,492
Ensembl chr 1:78,954,115...78,961,465
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
EXP |
4-hydroxy-2-nonenal promotes the reaction [FOSL1 protein binds to GGT1 promoter]; FOSL1 protein affects the reaction [4-hydroxy-2-nonenal results in increased activity of [JUN protein binds to JUND protein binds to JUNB protein]] |
CTD |
PMID:9890986 PMID:16195535 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Fosl2 |
FOS like 2, AP-1 transcription factor subunit |
multiple interactions |
EXP |
4-hydroxy-2-nonenal promotes the reaction [FOSL2 protein binds to GGT1 promoter] |
CTD |
PMID:16195535 |
|
NCBI chr 6:24,297,898...24,319,219
Ensembl chr 6:24,300,956...24,320,034
|
|
G |
Foxm1 |
forkhead box M1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FOXM1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO |
FOXO3 protein inhibits the reaction [SRT1720 inhibits the reaction [Tobacco Smoke Pollution results in increased abundance of 4-hydroxy-2-nonenal]] |
CTD |
PMID:24633890 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Foxp1 |
forkhead box P1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FOXP1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258
|
|
G |
Fpr3 |
formyl peptide receptor 3 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FPR3 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 1:58,884,427...58,893,472
Ensembl chr 1:58,845,118...58,893,467
|
|
G |
Fubp1 |
far upstream element binding protein 1 |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of FUBP1 mRNA |
CTD |
PMID:12419474 |
|
NCBI chr 2:241,159,481...241,186,591
Ensembl chr 2:241,159,512...241,186,602
|
|
G |
Fxn |
frataxin |
multiple interactions |
ISO |
4-hydroxy-2-nonenal affects the reaction [Ethanol affects the expression of FXN protein] |
CTD |
PMID:33017621 |
|
NCBI chr 1:221,874,007...221,897,543
Ensembl chr 1:221,872,420...221,897,540
|
|
G |
G6pd |
glucose-6-phosphate dehydrogenase |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of G6PDX mRNA |
CTD |
PMID:19191707 |
|
NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
4-hydroxy-2-nonenal results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:19191707 |
|
NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression multiple interactions |
ISO EXP |
4-hydroxy-2-nonenal results in increased expression of GADD45A mRNA Acetylcysteine inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of GADD45A mRNA] |
CTD |
PMID:19191707 PMID:24291486 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Gak |
cyclin G associated kinase |
decreases expression |
ISO |
4-hydroxy-2-nonenal results in decreased expression of GAK mRNA |
CTD |
PMID:12419474 |
|
NCBI chr14:1,089,853...1,164,098
Ensembl chr14:1,089,866...1,216,398
|
|
G |
Gapdh |
glyceraldehyde-3-phosphate dehydrogenase |
multiple interactions |
ISO |
[Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to GAPDH protein]] which results in decreased activity of GAPDH protein; [Hydroxyurea results in increased abundance of Free Radicals] promotes the reaction [4-hydroxy-2-nonenal binds to GAPDH protein]; Hydroxyurea promotes the reaction [4-hydroxy-2-nonenal binds to GAPDH protein] |
CTD |
PMID:20889679 PMID:23696560 |
|
NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
|
| |